Lorcaserin Extended-Release Tablets and Bradycardia
Result of checking the interaction of drug Lorcaserin Extended-Release Tablets and disease Bradycardia for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Lorcaserin may decrease heart rate. In clinical trials of at least one year duration, the mean decrease in heart rate was 1.2 beats per minute (bpm) in lorcaserin-treated and 0.4 bpm in placebo-treated patients without diabetes, and 2.0 bpm in lorcaserin-treated and 0.4 bpm in placebo-treated patients with type 2 diabetes. The incidence of heart rate less than 50 bpm was 5.3% in lorcaserin-treated and 3.2% in placebo-treated patients without diabetes, and 3.6% in lorcaserin-treated and 2.0% in placebo-treated patients with type 2 diabetes. In the combined population, adverse reactions of bradycardia occurred in 0.3% of lorcaserin-treated and 0.1% of placebo-treated patients. Therapy with lorcaserin should be administered cautiously in patients with bradycardia or a history of heart block greater than first degree.
Generic Name: lorcaserin
Brand Name: Belviq, Belviq XR
Synonyms: Lorcaserin